The TRAF3-DYRK1A-RAD54L2 complex maintains ACE2 expression to promote SARS-CoV-2 infection

Area of Science:

• Virology
• Molecular Biology
• Genetics

Background:

• Angiotensin converting enzyme 2 (ACE2) is the primary host receptor for SARS-CoV-2.
• ACE2 expression is critical for viral entry but its regulatory mechanisms are not fully understood.
• SARS-CoV-2 evolves through mutations to adapt to host environments.

Purpose of the Study:

• To identify host factors regulating ACE2 expression.
• To investigate mechanisms of SARS-CoV-2 adaptation to low ACE2 environments.
• To discover potential therapeutic targets against SARS-CoV-2.

Main Methods:

• Genome-wide CRISPR knockout screen to identify host factors.
• Analysis of SARS-CoV-2 replication in cells with varying ACE2 levels.
• Identification and functional analysis of mutations in SARS-CoV-2 spike (S) and nucleocapsid (N) proteins.

Main Results:

• The TDR complex (TRAF3, DYRK1A, RAD54L2) was identified as a regulator of ACE2 expression.
• Knockout of TDR complex components reduced ACE2 mRNA and inhibited SARS-CoV-2 entry.
• Mutations P1079T in spike and S194L in nucleocapsid enhance SARS-CoV-2 replication in low ACE2 cells.

Conclusions:

• The TDR complex represents a novel target for antiviral therapies.
• Understanding ACE2 regulation and viral adaptation mechanisms is key to combating SARS-CoV-2.
• Identified mutations provide insights into SARS-CoV-2 variant transmissibility and infectivity.